This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
In this discussion of ‘commercially reasonable efforts,’ Dr. Greg Bell explains how understanding the strategy behind a pharmaceutical product launch can inform development obligations in contract and licensing agreements. Click below to read the article.
Group Vice President and Life Sciences Practice Leader
Boston
+1-617-425-3357 gbell@crai.comReference country selection The model provided guidance on reference countries, defined by the G7 countries plus Denmark and Switzerland. Reference...
“The achievements of our newly promoted Vice Presidents reflect the great year that CRA had in 2025 and reinforce my optimism in our future,” said CRA...
CRA is a proud supporter of the conference where attendees span the full spectrum of the pharmacy and healthcare ecosystem, bringing together key...
CRA is a proud sponsor of the first-ever GAR Live: Life Sciences, evolving from the much-loved Technology Disputes event to reflect the growing complexity and...
